| Literature DB >> 19427857 |
Lin Jin1, Chuan-Le Xiao, Chun-Hua Lu, Min Xia, Guo-Wen Xing, Sheng Xiong, Qiu-Ying Liu, Hui Liu, Yi-Cheng Li, Feng Ge, Qing-Duan Wang, Qing-Yu He, Yi-Fei Wang.
Abstract
SNX-2112, a novel inhibitor of Hsp90 currently used as an anti-tumor drug, induces apoptosis in multiple tumor cell lines. It destabilizes specific client proteins, but the molecular mechanism of the apoptosis effect of SNX-2112 is poorly understood. Here, we analyzed the apoptotic effect of SNX-2112 on human chronic myeloid leukemia (CML) K562 cells. Transcriptomic and proteomic approaches further revealed that caspase signals originated from mitochondria dysfunction, mediated by Akt signaling pathway inactivity. Additionally, SNX-2112 prolonged the survival time of NOD/SCID mice inoculated with K562 tumor cells. Our results demonstrated the therapeutic potential of SNX-2112 against human CML.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19427857 DOI： 10.1016/j.febslet.2009.04.046
Source DB: PubMed Journal: FEBS Lett ISSN： 0014-5793 Impact factor: 4.124